Dr. Leu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8303 Dodge St
Ste 250
Omaha, NE 68114Phone+1 402-354-8124Fax+1 402-354-8127
Summary
- Dr. Kirsten Leu is an oncologist based in Omaha, NE. She completed her fellowship in Hematology and Medical Oncology at the University of Michigan Health System, a residency in Internal Medicine from the University of Wisconsin Hospitals and Clinics, and graduated from the University of Iowa Roy J. and Lucille A. Carver College of Medicine in 1996. Dr. Leu specializes in cancer research and treatment, evidenced by several highly cited publications in reputable journals, including "Cancers" and "Journal for Immunotherapy of Cancer". She has also participated in clinical trials and received the Meaningful Use Stage 1 Certification from the Centers for Medicare & Medicaid Services in 2012.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2000 - 2002
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1996 - 2000
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1996
Certifications & Licensure
IA State Medical License 2023 - 2026
NE State Medical License 2005 - 2026
MI State Medical License 2002 - 2006- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 15 citationsAssessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.Rashmi Chugh, T. Wagner, Kent A. Griffith, Jeremy M. G. Taylor, Dafydd G. Thomas
Cancer. 2007-06-01 - 67 citationsMulticenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1...Michael J. Wagner, Megan Othus, Sandip Pravin Patel, Christopher W. Ryan, Ashish Sangal
Journal for Immunotherapy of Cancer. 2021-08-01 - 189 citationsLaboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaKirsten M. Leu, Leo J. Ostruszka, Donna S. Shewach, Mark M. Zalupski, Vernon K. Sondak
Journal of Clinical Oncology. 2004-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
